Teduglutide Medicine 07 June 2022 Extended indication Extension of indication to include patients from 4 months corrected gestational aged 1 year and above Therapeutic value No estimate possible yet Total cost Registration phase Registration application pending Product Active substance Teduglutide Domain Chronic immune diseases Reason of inclusion Indication extension IND Main indication Bowel diseases Extended indication Extension of indication to include patients from 4 months corrected gestational aged 1 year and above Current proprietary name Already available biosimilars / generics Proprietary name Revestive Manufacturer Takeda Portfolio holder Mechanism of action Glucagon analogue Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date January 2022 Expected Registration November 2022 Orphan drug Yes Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 1 times a day Dosage per administration 0.05 mg per kg body weight References NCT03571516 Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks